Core Viewpoint - Yidu Technology (02158) announced that its affiliate Tianjin Happy Life Technology Co., Ltd. won a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.8176 million [1] Group 1 - Yidu Technology aims to drive AI medical transformation in China, adhering to the mission of making precision medicine accessible to everyone [1] - The company has developed a core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop, enabling efficient innovation and low-cost scalable applications of AI technology [1] - The value of medical AI is reflected in respecting individual lives and safeguarding health and well-being [1] Group 2 - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes [1] - Yidu Technology continuously improves the efficiency and accessibility of medical services, providing doctors with precise decision-making tools and enabling pharmaceutical companies to shorten the distance from molecules to patients [1] - Patients benefit from more affordable precision diagnosis and treatment, while public systems receive more scientific support [1]
医渡科技中标重组人神经生长因子(SMR001)滴眼液III期临床研究项目